Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line... o RIGINAL ARTICLE Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer Bilal Piperdi, MD,* William V. Walsh, MD,† Kendra Bradley, RN,† Zheng Zhou, MD, PhD,† Venu Bathini, MD,† Meredith Hanrahan-Boshes, RN,† Lloyd Hutchinson, PhD,‡ and Roman Perez-Soler, MD* (44%). The response rate, PFS, and overall survival in all patients Background: This study aimed to establish the maximum tolerated were 37.5% (95%CI 13.8%–61.2%), 5.0 months (95%CI: 3.1–8.4), dose (MTD) of weekly bortezomib in combination with fixed stan - 9.9 months (95% CI: 8.2–14.1), and among the 9 patients in phase-II dard doses of carboplatin and bevacizumab, and to estimate the effi - portion are 44% (95%CI 15.3%–77.3%), 5.5 months (95%CI: 3.1– cacy (response rate and progression free survival [PFS]) and safety of 2.2) and 10.9 months (95%CI: 8.0–14.1). combination therapy with carboplatin, bortezomib, and bevacizumab Conclusion: The recommended phase-II dose for this combination as first-line therapy in patients with advanced non–small-cell lung is: carboplatin AUC 6, bevacizumab 15 mg/kg on day 1 and bort- cancer (NSCLC). ezomib 1.8 mg/m on day 1 and day 8 on every 21-day cycle. The Methods: Patients were assigned to three dose levels http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Perez-Soler, Roman
Journal of Thoracic Oncology , Volume 7 (6) – Jun 1, 2012
Download PDF
9 pages

Loading next page...
 
/lp/wolters-kluwer-health/phase-i-sol-ii-study-of-bortezomib-in-combination-with-carboplatin-and-ByNsKJXcd5

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2012 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e31824de2fa
pmid
22534815
Publisher site
See Article on Publisher Site

Abstract

o RIGINAL ARTICLE Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer Bilal Piperdi, MD,* William V. Walsh, MD,† Kendra Bradley, RN,† Zheng Zhou, MD, PhD,† Venu Bathini, MD,† Meredith Hanrahan-Boshes, RN,† Lloyd Hutchinson, PhD,‡ and Roman Perez-Soler, MD* (44%). The response rate, PFS, and overall survival in all patients Background: This study aimed to establish the maximum tolerated were 37.5% (95%CI 13.8%–61.2%), 5.0 months (95%CI: 3.1–8.4), dose (MTD) of weekly bortezomib in combination with fixed stan - 9.9 months (95% CI: 8.2–14.1), and among the 9 patients in phase-II dard doses of carboplatin and bevacizumab, and to estimate the effi - portion are 44% (95%CI 15.3%–77.3%), 5.5 months (95%CI: 3.1– cacy (response rate and progression free survival [PFS]) and safety of 2.2) and 10.9 months (95%CI: 8.0–14.1). combination therapy with carboplatin, bortezomib, and bevacizumab Conclusion: The recommended phase-II dose for this combination as first-line therapy in patients with advanced non–small-cell lung is: carboplatin AUC 6, bevacizumab 15 mg/kg on day 1 and bort- cancer (NSCLC). ezomib 1.8 mg/m on day 1 and day 8 on every 21-day cycle. The Methods: Patients were assigned to three dose levels

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jun 1, 2012

References

  • Cancer Statistics 2004 CA Cancer
    Jemal
  • Chemotherapy in non-small cell lung cancer: a meta-analysis using data on individual patients from 52 randomized clinical trials
  • Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
    Schiller
  • Current standards of care in small-cell and non-small-cell lung cancer
    Schiller